Cost-Utility Analysis of First-Line Regimen Between Cisplatin Plus Pemetrexed and Carboplatin Plus Paclitaxel In Advanced Non-Squamous Non-Small-Cell Lung Cancer in Thailand
Nov 1, 2014, 00:00 AM
10.1016/j.jval.2014.08.118
https://www.valueinhealthjournal.com/article/S1098-3015(14)02048-8/fulltext
Section Title :
Disease-Specific Studies
Section Order :
2119
First Page :
A737
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(14)02048-8&doi=10.1016/j.jval.2014.08.118